# Suresh S. Ramalingam

Source: https://onco.cc/people/suresh-ramalingam/  
OnCo record `suresh-ramalingam` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lung cancer medical oncologist who leads Winship Cancer Institute of Emory University and led the FLAURA trial of osimertinib.

## Summary

Suresh S. Ramalingam is Executive Director of Winship Cancer Institute of Emory University, Georgia's NCI-designated comprehensive cancer centre. A thoracic medical oncologist, he was a principal investigator of the FLAURA trial establishing osimertinib as first-line therapy for EGFR-mutated non-small cell lung cancer, and has led numerous national lung cancer trials through ECOG-ACRIN.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: leadership; clinician-scientist; lung cancer; targeted therapy
- Role: Executive Director
- Specialisms: Lung cancer; Thoracic medical oncology; Targeted therapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Ramalingam+SS%5BAuthor%5D

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/), [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- institutions: [Winship Cancer Institute of Emory University](https://onco.cc/institutions/emory-winship/)
- trials: [FLAURA](https://onco.cc/trials/flaura/), [FLAURA2](https://onco.cc/trials/flaura2/)
- key papers: [Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC](https://onco.cc/key-papers/paper-lu-laura-osimertinib-stage-iii-nejm-2024/)

---
JSON: https://onco.cc/api/v1/entities/suresh-ramalingam.json